Compare Ascendis Pharma A/S (ASND) vs Mongodb Inc (MDB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Mongodb Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Mongodb Inc trades at $343.75 (market cap $27.51B). The key difference: Mongodb Inc is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MDB | |
|---|---|---|
Market Cap | $17.74B | $27.51B |
Sector | Health | Technology |
52-Week High | $277.18 | $440.25 |
52-Week Low | $163.32 | $201.08 |
Enterprise Value | $18.11B | $25.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MongoDB (MDB) trades at $342.08, down 5.73% in the latest session, amid mixed technical signals with a bullish moving average trend but overbought RSI readings. The company shows strong revenue growth, reaching $2.01B in 2025, with consistent earnings beats in recent quarters, though it remains unprofitable with a net margin of -1.12%. Recent news highlights AI-driven demand boosting database sales and raised FY2027 revenue guidance to $2.92–$2.96B.
Outlook remains positive with 82% analyst buy ratings and a $400.39 consensus target, offering ~17% upside. Key risks include ongoing profitability challenges, competitive pressures, and legal scrutiny over fiduciary duties. Revenue growth and AI adoption present opportunities, but investors should monitor margin improvement and execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
